Enavatuzumab

Enavatuzumab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Enavatuzumab is a monoclonal antibody that has been investigated for its potential use in the treatment of various types of cancer. It is a humanized antibody that targets the TWEAK receptor, also known as Fn14, which is a member of the tumor necrosis factor receptor superfamily.

Mechanism of Action

Enavatuzumab works by binding to the Fn14 receptor, which is overexpressed in many types of cancer cells. The binding of enavatuzumab to Fn14 can inhibit tumor growth and induce apoptosis in cancer cells. Additionally, enavatuzumab may enhance the immune system's ability to attack cancer cells by promoting antibody-dependent cellular cytotoxicity (ADCC).

Clinical Development

Enavatuzumab has been evaluated in several clinical trials to assess its safety and efficacy in treating cancers such as non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Early-phase trials have shown some promise, but further studies are needed to fully understand its therapeutic potential and to determine the optimal dosing regimens.

Side Effects

As with many monoclonal antibodies, enavatuzumab may cause side effects, including infusion reactions, fatigue, nausea, and potential immune-related adverse effects. The safety profile of enavatuzumab is still being characterized through ongoing clinical trials.

Research and Future Directions

Research is ongoing to explore the full potential of enavatuzumab in combination with other therapeutic agents, such as chemotherapy and immune checkpoint inhibitors. The goal is to enhance its efficacy and broaden its application across different cancer types.

Also see

• Monoclonal antibody therapy
• Cancer immunotherapy
• Tumor necrosis factor receptor
• Antibody-dependent cellular cytotoxicity